Last reviewed · How we verify

NCT04604444

Changes in Neuroplasticity Following Intensive Rehabilitation of Aphasia and/or Apraxia of Speech

Recruiting now NA Last updated 31 October 2024
What this trial tests

NA trial testing Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech in Aphasia in 30 participants. Currently enrolling.

Timeline
2 February 2017
Primary endpoint
31 December 2026
31 December 2027

Quick facts

Lead sponsorKarolinska Institutet
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date2 February 2017
Primary completion31 December 2026
Estimated completion31 December 2027
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Karolinska Institutet

Who can join

Adults 18 to 75, any sex, with Aphasia or Apraxia of Speech. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aims to investigate the short- and long-term effects of two weeks of intensive speech-language pathology intervention with additional physiotherapy, on aphasia and apraxia of speech (AOS) and their neural correlates in thirty persons with chronic stroke. Changes are studied following intensive treatment of aphasia and AOS with standardised speech-language testing and testing of communication and with voxel-based morphometry (VBM) analysis and resting state functional connectivity (rsFC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aphasia

Currently open trials in the same condition.

Other Karolinska Institutet trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04604444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing